China gives nod to new seaweed-based Alzheimer’s drug Oligomannate
Category: #health  By Saipriya Iyer  Date: 2019-11-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

China gives nod to new seaweed-based Alzheimer’s drug Oligomannate

The Chinese government has reportedly approved world’s first drug in 20 years for treating Alzheimer’s disease. It took around two decades to develop the drug and it is being considered as the only treatment having the potential to reverse the condition.

The National Medical Products Administration stated that the drug, Oligomannate, that is claimed to treat mild to relatively moderate Alzheimer’s disease as well as improve the cognitive function, has finally got its approval.

Apparently, the development of the drug had taken inspiration from observations stating that elderly people who regularly consumed seaweed experienced low occurrence of Alzheimer’s.

Dr. Geng Meiyu, who led the Chinese research team at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences had delved into the matter to look for a possible connection and eventually identified a particular sugar present in seaweed that potentially plays an important part in the process.

Alzheimer’s causes a decline in the functioning of the brain which is divided into seven stages. Seemingly, the new drug can be effective up to the stage 4 of the condition that may include recalling what food the patient had for breakfast, difficulty in adding up simple numbers, remembering simple details about their life history and paying bills.

Pharmaceutical companies have been investing billions of U.S. dollars from the past two decades with over 320 candidate drugs brought in for clinical trials. Out of several of these, only five had been approved that could relieve the symptoms but could not prevent the brain cells from withering. Major programs related to Alzheimer’s had to be terminated in several large medical companies due to the constant expensive failures. 

Geng’s team had published a paper in September and announced an important discovery. The team discovered that Oligomannate was a multitasking agent which curbs the formation of a particular protein damaging to neurons as well as regulates the colonies of bacterium in the human intestines in order to reduce the dangers of brain inflammation.
 

Source Credit- https://www.scmp.com/news/china/science/article/3036119/china-approves-oligomannate-worlds-first-new-alzheimers-drug-20



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...